GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

faricimab   Click here for help

GtoPdb Ligand ID: 11420

Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
Approved drug
faricimab is an approved drug (EMA & FDA (2022))
Compound class: Antibody
Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2024)  |  EU EMA (2022)  |  US FDA (2022)
International Nonproprietary Names Click here for help
INN number INN
10563 faricimab
Synonyms Click here for help
faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 793
Other databases
GtoPdb PubChem SID 440816789
Search PubMed clinical trials faricimab
Search PubMed titles faricimab
Search PubMed titles/abstracts faricimab